Although it’s a long way from the president’s desk, the Tax Cut and Jobs Act of 2017 contains plenty of good news for the life sciences industry and its marketing partners.
Five things for pharma marketers to know: Tuesday, December 5, 2017
FDA to change Risk Evaluation Mitigation Strategies to prevent delayed generic approvals; Ohio rejects drug-price measure; Aetna CEO wants to improve in-person pharmacy experience
Five things for pharma marketers to know: Wednesday, November 1, 2017
Drug industry spends nearly $50 million to fight drug-price referendum; Novartis weighs sales of generic unit; ICER to evaluate all newly approved drugs
Five things for pharma marketers to know: Thursday, October 26, 2017
FDA develops resources about biosimilars for HCPs; Biogen negotiates royalties for experimental Alzheimer’s drug; GSK Q3 sales driven by HIV, respiratory drugs
AbbVie adds context to CEO’s comments on drug pricing; Pandora makes a play for pharma ad dollars; shortages expected of drugs manufactured in Puerto Rico